

Clinical value of thyroid-stimulating immunoglobulin in paediatric autoimmune thyroid diseases



Karolina Stożek¹, Artur Bossowski¹, Katarzyna Ziara², Anna Bossowska³, Tanja Diana⁴, George J Kahaly⁴.

1 Department of Pediatric Endocrinology, Diabetology with Cardiology Division, Medical University of Białystok, Poland. 2 Department of Pediatrics, Silesian Medical University, 3 Division of Cardiology, Internal Affairs Ministry Hospital in Białystok, Poland, 4 Molecular Thyroid Research Laboratory, Johannes Gutenberg University (JGU) Medical Center, Mainz 55101, Germany.


OBJECTIVE

In Autoimmune Thyroid Diseases (AITD) two types of TSH receptor antibodies (TSHR-Ab) may be distinguished: thyroid-stimulating immunoglobulin (TSI) that promotes the production of thyroid hormones and thyroid-blocking immunoglobulin (TBI) inhibiting the activity of TSH what leads contrarily to hypothyroidism. The aim of this study was to compare mean TSI and TBI levels in large paediatric cohort with AITD and control.

METHODS

TSHR-Abs imitate the receptor's ligand by elevating (TSI) cAMP level in thyroid cells or act as antagonists (TBI) inhibiting cAMP production. It is utilized in novel, cell-based tests (bioassays), which measure luciferase activity induced by cAMP. Chinese hamster ovary cells, stably express a chimeric human TSH-receptor. Available bioassays can differentiate whether TSHR-Abs have stimulatory or blocking properties. Results relevant to TSI are presented as percentage of specimen-to-reference ratio (SRR%, cutoff **140%**). TBIs are reported as percentage of inhibition –cutoff **40%**.

Fig.1 Model of TSH-R bioassay



TSHR-Ab from tested sample binds to the TSH receptor and triggers the cAMP signaling cascade, what finally results in the light emission.

Fig.2 Laboratory features of all study groups

	GD	HT	Dt1	JIA	C
n	53	83	66	5	33
TSH (uIU/ml)	1.12±2.13* (p=0.01**)	8.16±19.79 (n.s.***)	2.46±1.13	2.3±1.45	2.3±1.02
ft4 (ng/ml)	2.56±1.61 (p<0.0001**)	1.27±0.34 (n.s.***)	-	-	1.3±0.19
ft3 (pg/ml)	6.39±4.82 (p=0.001**)	3.27±1.08 (n.s.***)	-	-	3.84±0.95
Treatment	Metizol	L-thyroxin			

*mean ± SD
**p: statistical significance between GD and HT
***p: statistical significance between GD and C
**** statistical significance between HT and C

Fig.3 Positive values of TSHR-Abs in all GD (n=53) and HT (n=83) samples




Fig.4 TSI levels in samples with GD vs. GO




Fig.5 Mean TSI levels in HT and HO




Fig.6 Proportion between TSI's positive values in HT and HO





Fig.7 TSI levels in all study groups



RESULTS

A total of 240 serum samples were obtained from 206 paediatric patients with autoimmune diseases: 33 with Graves' disease (GD, 29 female, mean age SD 13.18 4.22 years), 69 with Hashimoto's thyroiditis (HT, 58 female, 13.33 2.98 yrs), 66 with type 1 diabetes (Dt1, 32 female, 13.43 3.17 yrs), 5 with juvenile arthritis (JA, 2 female, 13.8 3.27yrs) and 33 healthy controls (C, 11 female, 11.85 4.56 yrs).

CONCLUSION

1. These results indicate strong correlation between TSI and GD.
2. Occurrence of orbitopathy associates with TSI's presence both in GD and HT.
3. Higher TSI levels in group with vs. without TAO are observed.
4. TBI's utility seems to be uncertain.

REFERENCES

1. Lytton SD., Kahaly GJ. Bioassays for TSH-receptor autoantibodies: An update. Autoimmunity Rev. 2010 Dec;10(2):116-22.
2. Kampmann E., Diana T., Kanitz M., Hoppe D., and Kahaly GJ. Thyroid Stimulating but Not Blocking Autoantibodies Are Highly Prevalent in Severe and Active Thyroid-Associated Orbitopathy: A Prospective Study. International Journal of Endocrinology, vol. 2015, Article ID 678194, 5 pages, 2015.
3. Ponto KA., Kanitz M., Olivo PD., Pitz S., Pfeiffer N., Kahaly GJ. Clinical relevance of thyroid-stimulating immunoglobulins in Graves' ophthalmopathy. Ophthalmology. 2011 Nov;118(11):2279-85.
4. Diana T., Brown RS., Bossowski A., Segni M., Niedziela M., König J., Bossowska A., Ziara K., Hale A., Smith J., Pitz S., Kanitz M., Kahaly GJ. Clinical Relevance of Thyroid-Stimulating Autoantibodies in Pediatric Graves' Disease- A Multicenter Study. The Journal of Clinical Endocrinology. 2014 May;99(5):1648-55.

